News Category
Two peer-reviewed papers show BV100 achieves high lung concentrations and has a manageable drug-interaction profile, bolstering its potential as a muc...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article that highlighted promising but li...
The American Heart Association's 2026 Health Tech Competition finalists aim to overcome adoption barriers and transform cardiovascular and brain healt...
NanoViricides' Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo virus marks a critical step for a broad-spectrum antiviral that could addre...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to execute a Phase 2 trial of Lucid-MS, a nove...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS signals a potential paradigm shift...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business marks a critical step toward testing a first-in-class neuroprotective th...
XORTX Therapeutics is positioning its proprietary gout treatment XORLO for a New Drug Application submission to the FDA within a year, aiming to addre...
Quantum BioPharma has entered a Study Start-Up Agreement with Thermo Fisher Scientific to initiate its Phase 2 trial of Lucid-MS for multiple sclerosi...
NanoViricides' upcoming presentation at the NIBA 153rd Investment Conference highlights its progress on NV-387, a broad-spectrum antiviral in Phase 2 ...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher's clinical research business marks a critical step toward launching a Phase 2 trial fo...
Okogen's CDSCO authorization for the EMERALD Phase 1/2 study of Treyegen (OKG-0303) marks a significant step toward a single therapy for viral and bac...
NanoViricides has initiated a Phase II clinical trial of its oral NV-387 gummies for Ebola, a potential breakthrough for outbreak response in resource...
Quantum BioPharma's Lucid-MS is entering a Phase 2 trial in multiple sclerosis patients, marking a significant milestone for the company and potential...
NanoViricides has started enrolling and dosing patients in a Phase II clinical trial of its oral antiviral NV-387 for Bundibugyo Ebolavirus in the Dem...
In vitro ADME studies are critical for early assessment of drug candidates, helping to avoid costly late-stage failures and streamline development.
A new study reveals that individual bacterial strains in the microbiome affect the risk of sepsis, meningitis, and pneumonia from air pollution, highl...
Peptide Wholesale Supply now applies HPLC testing to every batch of BPC-157, Semaglutide, and Tirzepatide in bulk orders, providing researchers with d...
Patients with small cell lung cancer should ask about clinical trials at their first appointment, as timing can be crucial and emerging therapies offe...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for independent testing of GEO-MVA could strengthen regulatory confidence and h...
Tevard Biosciences announced preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has broadened its functionalized lipid-based delivery capabilities to help researchers overcome stability, targeting, and controlled ...
BioCorRx Inc. has appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Adviso...
Regentis Biomaterials reported first half 2026 results, highlighting progress in its Phase III GelrinC trial, a 400% yield increase in manufacturing, ...
Quantum BioPharma's FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class myelin-protecting and rebuilding candidate, could transform ...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, as an FDA-authorized pivotal tria...
VERAXA Biotech's appointment of Dr. Christoph Erkel as Chief Scientific Officer signals a strategic push to advance its conditionally active BiTAC® T-...
Quantum BioPharma receives FDA clearance to launch a phase 2 trial of Lucid-MS, the first drug designed to shield and rebuild myelin in multiple scler...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to proceed to a Phase 2 trial in multiple scler...
Quantum BioPharma's Lucid-MS becomes the first drug designed to protect and rebuild myelin to enter human testing for multiple sclerosis, potentially ...
Helus Pharma CEO Michael Halstead's upcoming fireside chat at the Morgan Stanley Global Healthcare Conference highlights the company's late-stage deve...
Onco-Innovations' CMO discusses the potential of ONC010, a novel PNKP inhibitor with dual selectivity mechanisms, as it advances toward first-in-human...
Quantum BioPharma's FDA clearance of its IND application for Lucid-MS marks a critical step toward a Phase 2 trial in multiple sclerosis, potentially ...
An expert highlights the overlooked challenges in diagnosing urinary tract infections (UTIs), underscoring the need for improved diagnostic tools to a...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its progress in developing SPC-15, a nose-to-brain drug delivery sy...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial highlights a novel approach to MS that could protect and repair myelin, not just suppress...
Quantum BioPharma's Lucid-MS has received FDA clearance to begin a Phase 2 clinical trial, a rare milestone for a micro-cap biotech that could validat...
GeoVax endorses the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to bolster diversified supply and preparedness.
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to enhance its financial leadership and support its oncology pipeline de...
Scinai Immunotherapeutics strategically pivots its R&D to its NanoAb platform and CDMO services after terminating its PC111 license, aiming to optimiz...
Onco-Innovations advances its oncology pipeline with manufacturing and IND-enabling progress, strategic partnerships, and new funding, positioning ONC...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in Phase 2 trials marks a potential paradigm shift in MS tre...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Ocumetics Technology Corp. has begun recruiting patients for its Group Two human clinical study of its next-generation accommodating intraocular lens,...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, marks a potential paradigm shift in treat...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Pan African Clinical Trials Registry, marking a critical step in ...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS marks a critical step toward a novel treatment that targets demyelination in mu...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a novel demyelination-targeting drug, could redefine MS therapy by addressing ...
